AUTH:"Essink B" - Search results

Safety and immunogenicity of a modified mRNA-lipid nanoparticle vaccine candidate against COVID-19: Results from a phase 1, dose-escalation study.

Essink BJ, Shapiro C, Isidro MGD, Bradley P, Pragalos A, Bloch M, Santiaguel J, Frias MV, Miyakis S, Alves de Mesquita M, Berrè S, Servais C, Waugh N, Hoffmann C, Baba E, Schönborn-Kellenberger O, Wolz OO, Koch SD, Ganyani T, [...] Vanhoutte N

Hum Vaccin Immunother, 20(1):2408863, 18 Oct 2024

Cited by: 0 articles | PMID: 39422261 | PMCID: PMC11492660

Add to export list

This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.

Free full text in Europe PMC

Safety and Immunogenicity of an mRNA-Based RSV Vaccine Including a 12-Month Booster in a Phase 1 Clinical Trial in Healthy Older Adults.

Shaw CA, Essink B, Harper C, Mithani R, Kapoor A, Dhar R, Wilson L, Guo R, Panozzo CA, Wilson E, Simorellis AK, Reuter C, Stoszek SK, Chen GL, Das R, Goswami J

J Infect Dis, 230(3):e647-e656, 01 Sep 2024

Cited by: 2 articles | PMID: 38385566 | PMCID: PMC11420773

Add to export list

This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.

Free full text in Europe PMC

Long-term safety and effectiveness of mRNA-1273 vaccine in adults: COVE trial open-label and booster phases.

Baden LR, El Sahly HM, Essink B, Follmann D, Hachigian G, Strout C, Overcash JS, Doblecki-Lewis S, Whitaker JA, Anderson EJ, Neuzil K, Corey L, Priddy F, Tomassini JE, Brown M, Girard B, Stolman D, Urdaneta V, Wang X, [...] COVE Trial Consortium

Nat Commun, 15(1):7469, 29 Aug 2024

Cited by: 0 articles | PMID: 39209823 | PMCID: PMC11362294

Add to export list

This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.

Free full text in Europe PMC

Interim Report of the Reactogenicity and Immunogenicity of Severe Acute Respiratory Syndrome Coronavirus 2 XBB-Containing Vaccines.

Chalkias S, McGhee N, Whatley JL, Essink B, Brosz A, Tomassini JE, Girard B, Edwards DK, Wu K, Nasir A, Lee D, Avena LE, Feng J, Deng W, Montefiori DC, Baden LR, Miller JM, Das R

J Infect Dis, 230(2):e279-e286, 01 Aug 2024

Cited by: 17 articles | PMID: 38349280 | PMCID: PMC11326827

Add to export list

This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.

Free full text in Europe PMC

Efficacy and Safety of Respiratory Syncytial Virus (RSV) Prefusion F Protein Vaccine (RSVPreF3 OA) in Older Adults Over 2 RSV Seasons.

Ison MG, Papi A, Athan E, Feldman RG, Langley JM, Lee DG, Leroux-Roels I, Martinon-Torres F, Schwarz TF, van Zyl-Smit RN, Verheust C, Dezutter N, Gruselle O, Fissette L, David MP, Kostanyan L, Hulstrøm V, Olivier A, Van der Wielen M, [...] AReSVi-006 Study Group

Clin Infect Dis, 78(6):1732-1744, 01 Jun 2024

Cited by: 13 articles | PMID: 38253338

Add to export list

Safety and Immunogenicity of an mRNA-Based hMPV/PIV3 Combination Vaccine in Seropositive Children.

Schnyder Ghamloush S, Essink B, Hu B, Kalidindi S, Morsy L, Egwuenu-Dumbuya C, Kapoor A, Girard B, Dhar R, Lackey R, Snape MD, Shaw CA

Pediatrics, 153(6):e2023064748, 01 Jun 2024

Cited by: 1 article | PMID: 38738290

Add to export list

SARS-CoV-2 Viral Load in the Nasopharynx at Time of First Infection Among Unvaccinated Individuals: A Secondary Cross-Protocol Analysis of 4 Randomized Trials.

Fisher LH, Kee JJ, Liu A, Espinosa CM, Randhawa AK, Ludwig J, Magaret CA, Robinson ST, Gilbert PB, Hyrien O, Kublin JG, Rouphael N, Falsey AR, Sobieszczyk ME, El Sahly HM, Grinsztejn B, Gray GE, Kotloff KL, Gay CL, [...] COVID-19 Prevention Network (CoVPN)

JAMA Netw Open, 7(5):e2412835, 01 May 2024

Cited by: 1 article | PMID: 38780941 | PMCID: PMC11117088

Add to export list

This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.

Free full text in Europe PMC

A Bivalent Omicron-BA.4/BA.5-Adapted BNT162b2 Booster in ≥12-Year-Olds.

Usdan L, Patel S, Rodriguez H, Xu X, Lee DY, Finn D, Wyper H, Lowry FS, Mensa FJ, Lu C, Cooper D, Koury K, Anderson AS, Türeci Ö, Şahin U, Swanson KA, Gruber WC, Kitchin N, C4591044 Study Group

Clin Infect Dis, 78(5):1194-1203, 01 May 2024

Cited by: 4 articles | PMID: 38016021 | PMCID: PMC11093671

Add to export list

This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.

Free full text in Europe PMC

Long-term safety and efficacy of COVE study open-label and booster phases

Baden L, Sahly HE, Essink B, Follmann D, Hachigian G, Strout C, Overcash JS, Doblecki-Lewis S, Whitaker J, Anderson E, Neuzil K, Corey L, Priddy F, Tomassini J, Brown M, Girard B, Stolman D, Urdaneta V, Wang X, [...] Miller J

Research Square, 14 Mar 2024

Cited by: 0 articles | PPR: PPR821994

Add to export list Preprint v1

The respiratory syncytial virus prefusion F protein vaccine attenuates the severity of respiratory syncytial virus-associated disease in breakthrough infections in adults ≥60 years of age.

Curran D, Matthews S, Cabrera ES, Pérez SN, Breva LP, Rämet M, Helman L, Park DW, Schwarz TF, Melendez IMG, Schaefer A, Roy N, Stephan B, Molnar D, Kostanyan L, Powers JH, Hulstrøm V, Members of the AReSVi‐006 Study Group

Influenza Other Respir Viruses, 18(2):e13236, 03 Feb 2024

Cited by: 3 articles | PMID: 38314063 | PMCID: PMC10837780

Add to export list

This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.

Free full text in Europe PMC

Respiratory Syncytial Virus Prefusion F Protein Vaccine Is Efficacious in Older Adults With Underlying Medical Conditions.

Feldman RG, Antonelli-Incalzi R, Steenackers K, Lee DG, Papi A, Ison MG, Fissette L, David MP, Maréchal C, Van der Wielen M, Kostanyan L, Hulstrøm V, AReSVi-006 Study Group

Clin Infect Dis, 78(1):202-209, 01 Jan 2024

Cited by: 13 articles | PMID: 37698366 | PMCID: PMC10810713

Add to export list

This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.

Free full text in Europe PMC

A review of the immunogenicity and safety of booster doses of omicron variant-containing mRNA-1273 COVID-19 vaccines in adults and children.

Priddy F, Chalkias S, Essink B, Whatley J, Brosz A, Lee IT, Feng J, Tracy L, Deng W, Zhou W, Zhou H, Dixit A, Schnyder-Ghamloush S, Girard B, de Windt E, Yeakey A, Miller J, Das R, Kuter BJ

Expert Rev Vaccines, 23(1):862-878, 01 Jan 2024

Cited by: 0 articles | PMID: 39234779

Add to export list Review

Safety and immunogenicity of three dose levels of an investigational, highly purified Vero cell rabies vaccine: A randomized, controlled, observer-blinded, Phase II study with a simulated post-exposure regimen in healthy adults.

Pichon S, Guinet-Morlot F, Saleh J, Essink B, Pineda-Peña AC, Moureau A, Petit C, Minutello AM

Hum Vaccin Immunother, 19(3):2275453, 03 Nov 2023

Cited by: 1 article | PMID: 37921410 | PMCID: PMC10627063

Add to export list

This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.

Free full text in Europe PMC

Risk of COVID-19 after natural infection or vaccination.

Rick AM, Laurens MB, Huang Y, Yu C, Martin TCS, Rodriguez CA, Rostad CA, Maboa RM, Baden LR, El Sahly HM, Grinsztejn B, Gray GE, Gay CL, Gilbert PB, Janes HE, Kublin JG, Huang Y, Leav B, Hirsch I, [...] NIAID-funded COVID-19 Prevention Network (CoVPN)

EBioMedicine, 96:104799, 20 Sep 2023

Cited by: 2 articles | PMID: 37738833 | PMCID: PMC10518569

Add to export list

This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.

Free full text in Europe PMC

Original SARS-CoV-2 monovalent and Omicron BA.4/BA.5 bivalent COVID-19 mRNA vaccines: phase 2/3 trial interim results.

Chalkias S, Whatley JL, Eder F, Essink B, Khetan S, Bradley P, Brosz A, McGhee N, Tomassini JE, Chen X, Zhao X, Sutherland A, Shen X, Girard B, Edwards DK, Feng J, Zhou H, Walsh S, Montefiori DC, [...] Das R

Nat Med, 29(9):2325-2333, 31 Aug 2023

Cited by: 15 articles | PMID: 37653342 | PMCID: PMC10504066

Add to export list

This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.

Free full text in Europe PMC

Safety and Immunogenicity of XBB.1.5-Containing mRNA Vaccines

Chalkias S, McGhee N, Whatley JL, Essink B, Brosz A, Tomassini JE, Girard B, Wu K, Edwards DK, Nasir A, Lee D, Avena LE, Feng J, Deng W, Montefiori DC, Baden LR, Miller JM, Das R

medRxiv, 24 Aug 2023

Cited by: 0 articles | PPR: PPR705229

Add to export list Preprint

This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.

Free full text in Europe PMC

Three-month antibody persistence of a bivalent Omicron-containing booster vaccine against COVID-19.

Chalkias S, Harper C, Vrbicky K, Walsh SR, Essink B, Brosz A, McGhee N, Tomassini JE, Chen X, Ying Chang, Sutherland A, Montefiori DC, Girard B, Edwards DK, Jing Feng, Zhou H, Baden LR, Miller JM, Das R

Nat Commun, 14(1):5125, 23 Aug 2023

Cited by: 11 articles | PMID: 37612300 | PMCID: PMC10447540

Add to export list

This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.

Free full text in Europe PMC

Safety and immunogenicity of a variant-adapted SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant as a booster in adults primed with authorized vaccines: a phase 3, parallel-group study.

de Bruyn G, Wang J, Purvis A, Ruiz MS, Adhikarla H, Alvi S, Bonaparte MI, Brune D, Bueso A, Canter RM, Ceregido MA, Deshmukh S, Diemert D, Finn A, Forrat R, Fu B, Gallais J, Griffin P, Grillet MH, [...] VAT00002 booster cohorts study team

EClinicalMedicine, 62:102109, 22 Jul 2023

Cited by: 13 articles | PMID: 37533419 | PMCID: PMC10391925

Add to export list

This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.

Free full text in Europe PMC

Clinical and Demographic Factors Associated With COVID-19, Severe COVID-19, and SARS-CoV-2 Infection in Adults: A Secondary Cross-Protocol Analysis of 4 Randomized Clinical Trials.

Theodore DA, Branche AR, Zhang L, Graciaa DS, Choudhary M, Hatlen TJ, Osman R, Babu TM, Robinson ST, Gilbert PB, Follmann D, Janes H, Kublin JG, Baden LR, Goepfert P, Gray GE, Grinsztejn B, Kotloff KL, Gay CL, [...] COVID-19 Prevention Network (CoVPN)

JAMA Netw Open, 6(7):e2323349, 03 Jul 2023

Cited by: 8 articles | PMID: 37440227 | PMCID: PMC10346130

Add to export list

This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.

Free full text in Europe PMC

Cardiovascular Safety of Testosterone-Replacement Therapy.

Lincoff AM, Bhasin S, Flevaris P, Mitchell LM, Basaria S, Boden WE, Cunningham GR, Granger CB, Khera M, Thompson IM, Wang Q, Wolski K, Davey D, Kalahasti V, Khan N, Miller MG, Snabes MC, Chan A, Dubcenco E, [...] TRAVERSE Study Investigators

N Engl J Med, 389(2):107-117, 16 Jun 2023

Cited by: 45 articles | PMID: 37326322

Add to export list

The safety and immunogenicity of two Zika virus mRNA vaccine candidates in healthy flavivirus baseline seropositive and seronegative adults: the results of two randomised, placebo-controlled, dose-ranging, phase 1 clinical trials.

Essink B, Chu L, Seger W, Barranco E, Le Cam N, Bennett H, Faughnan V, Pajon R, Paila YD, Bollman B, Wang S, Dooley J, Kalidindi S, Leav B

Lancet Infect Dis, 23(5):621-633, 19 Jan 2023

Cited by: 26 articles | PMID: 36682364

Add to export list

Safety, Immunogenicity, and Efficacy of the NVX-CoV2373 COVID-19 Vaccine in Adolescents: A Randomized Clinical Trial.

Áñez G, Dunkle LM, Gay CL, Kotloff KL, Adelglass JM, Essink B, Campbell JD, Cloney-Clark S, Zhu M, Plested JS, Roychoudhury P, Greninger AL, Patel N, McGarry A, Woo W, Cho I, Glenn GM, Dubovsky F, 2019nCoV-301–Pediatric Expansion Study Group

JAMA Netw Open, 6(4):e239135, 03 Apr 2023

Cited by: 20 articles | PMID: 37099299 | PMCID: PMC10536880

Add to export list

This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.

Free full text in Europe PMC

Safety and Immunogenicity of Omicron BA.4/BA.5 Bivalent Vaccine Against Covid-19

Chalkias S, Whatley J, Eder F, Essink B, Khetan S, Bradley P, Brosz A, McGhee N, Tomassini JE, Chen X, Zhao X, Sutherland A, Shen X, Girard B, Edwards DK, Feng J, Zhou H, Walsh S, Montefiori DC, [...] Das R

medRxiv, 13 Dec 2022

Cited by: 0 articles | PPR: PPR583497

Add to export list Preprint

This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.

Free full text in Europe PMC

Immunogenicity and safety of concomitant and sequential administration of yellow fever YF-17D vaccine and tetravalent dengue vaccine candidate TAK-003: A phase 3 randomized, controlled study.

Tricou V, Essink B, Ervin JE, Turner M, Escudero I, Rauscher M, Brose M, Lefevre I, Borkowski A, Wallace D

PLoS Negl Trop Dis, 17(3):e0011124, 08 Mar 2023

Cited by: 4 articles | PMID: 36888687 | PMCID: PMC9994689

Add to export list

This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.

Free full text in Europe PMC

Respiratory Syncytial Virus Prefusion F Protein Vaccine in Older Adults.

Papi A, Ison MG, Langley JM, Lee DG, Leroux-Roels I, Martinon-Torres F, Schwarz TF, van Zyl-Smit RN, Campora L, Dezutter N, de Schrevel N, Fissette L, David MP, Van der Wielen M, Kostanyan L, Hulstrøm V, AReSVi-006 Study Group

N Engl J Med, 388(7):595-608, 01 Feb 2023

Cited by: 168 articles | PMID: 36791160

Add to export list

Search life-sciences literature (45,100,050 articles, preprints and more)

Search results

Safety and immunogenicity of a modified mRNA-lipid nanoparticle vaccine candidate against COVID-19: Results from a phase 1, dose-escalation study.

Safety and Immunogenicity of an mRNA-Based RSV Vaccine Including a 12-Month Booster in a Phase 1 Clinical Trial in Healthy Older Adults.

Long-term safety and effectiveness of mRNA-1273 vaccine in adults: COVE trial open-label and booster phases.

Interim Report of the Reactogenicity and Immunogenicity of Severe Acute Respiratory Syndrome Coronavirus 2 XBB-Containing Vaccines.

Efficacy and Safety of Respiratory Syncytial Virus (RSV) Prefusion F Protein Vaccine (RSVPreF3 OA) in Older Adults Over 2 RSV Seasons.

Safety and Immunogenicity of an mRNA-Based hMPV/PIV3 Combination Vaccine in Seropositive Children.

SARS-CoV-2 Viral Load in the Nasopharynx at Time of First Infection Among Unvaccinated Individuals: A Secondary Cross-Protocol Analysis of 4 Randomized Trials.

A Bivalent Omicron-BA.4/BA.5-Adapted BNT162b2 Booster in ≥12-Year-Olds.

Long-term safety and efficacy of COVE study open-label and booster phases

The respiratory syncytial virus prefusion F protein vaccine attenuates the severity of respiratory syncytial virus-associated disease in breakthrough infections in adults ≥60 years of age.

Respiratory Syncytial Virus Prefusion F Protein Vaccine Is Efficacious in Older Adults With Underlying Medical Conditions.

A review of the immunogenicity and safety of booster doses of omicron variant-containing mRNA-1273 COVID-19 vaccines in adults and children.

Safety and immunogenicity of three dose levels of an investigational, highly purified Vero cell rabies vaccine: A randomized, controlled, observer-blinded, Phase II study with a simulated post-exposure regimen in healthy adults.

Risk of COVID-19 after natural infection or vaccination.

Original SARS-CoV-2 monovalent and Omicron BA.4/BA.5 bivalent COVID-19 mRNA vaccines: phase 2/3 trial interim results.

Safety and Immunogenicity of XBB.1.5-Containing mRNA Vaccines

Three-month antibody persistence of a bivalent Omicron-containing booster vaccine against COVID-19.

Safety and immunogenicity of a variant-adapted SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant as a booster in adults primed with authorized vaccines: a phase 3, parallel-group study.

Clinical and Demographic Factors Associated With COVID-19, Severe COVID-19, and SARS-CoV-2 Infection in Adults: A Secondary Cross-Protocol Analysis of 4 Randomized Clinical Trials.

Cardiovascular Safety of Testosterone-Replacement Therapy.

The safety and immunogenicity of two Zika virus mRNA vaccine candidates in healthy flavivirus baseline seropositive and seronegative adults: the results of two randomised, placebo-controlled, dose-ranging, phase 1 clinical trials.

Safety, Immunogenicity, and Efficacy of the NVX-CoV2373 COVID-19 Vaccine in Adolescents: A Randomized Clinical Trial.

Safety and Immunogenicity of Omicron BA.4/BA.5 Bivalent Vaccine Against Covid-19

Immunogenicity and safety of concomitant and sequential administration of yellow fever YF-17D vaccine and tetravalent dengue vaccine candidate TAK-003: A phase 3 randomized, controlled study.

Respiratory Syncytial Virus Prefusion F Protein Vaccine in Older Adults.

Partnerships & funding